Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone805-562-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$68.13 million
Profitability
Miscellaneous
Employees259
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra Inc (NASDAQ:SIEN) announced its earnings results on Thursday, August, 8th. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.69) by $0.50. The medical instruments supplier had revenue of $20.53 million for the quarter, compared to the consensus estimate of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The firm's revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.73) earnings per share. View Sientra's Earnings History.
When is Sientra's next earnings date?
What guidance has Sientra issued on next quarter's earnings?
Sientra updated its FY 2019 earnings guidance on Thursday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $79-83 million, compared to the consensus revenue estimate of $81.13 million.
What price target have analysts set for SIEN?
8 equities research analysts have issued 12 month price targets for Sientra's shares. Their predictions range from $10.00 to $27.00. On average, they expect Sientra's share price to reach $15.75 in the next twelve months. This suggests a possible upside of 139.7% from the stock's current price. View Analyst Price Targets for Sientra.
What is the consensus analysts' recommendation for Sientra?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra.
Has Sientra been receiving favorable news coverage?
News coverage about SIEN stock has trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sientra earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Sientra.
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Inogen (INGN), Establishment Labs (ESTA), RTI Surgical (RTIX), Invacare (IVC), ConforMIS (CFMS), Lakeland Industries (LAKE), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Histogenics (HSGX), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Wound Management Technologies (WNDM), Bionik Laboratories (BNKL), Allied Healthcare Products (AHPI) and Avitar (AVTI).
What other stocks do shareholders of Sientra own?
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 72)
- Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 48)
- Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 61)
- Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 54)
- Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.
Who are Sientra's major shareholders?
Sientra's stock is owned by a number of of institutional and retail investors. Top institutional investors include UBS Group AG (5.39%), Vanguard Group Inc. (6.36%), BlackRock Inc. (6.08%), Bamco Inc. NY (5.05%), Schroder Investment Management Group (4.28%) and Schroder Investment Management Group (4.28%). Company insiders that own Sientra stock include Jeffrey M Nugent, Keith J Sullivan, Patrick F Williams, Paul Sean Little, R Scott Greer and Timothy Haines. View Institutional Ownership Trends for Sientra.
Which major investors are selling Sientra stock?
SIEN stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Bank of New York Mellon Corp, MUFG Securities EMEA plc, UBS Asset Management Americas Inc., Tower Research Capital LLC TRC , Parametric Portfolio Associates LLC and Morgan Stanley. Company insiders that have sold Sientra company stock in the last year include Jeffrey M Nugent and Timothy Haines. View Insider Buying and Selling for Sientra.
Which major investors are buying Sientra stock?
SIEN stock was acquired by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Schroder Investment Management Group, UBS Group AG, Vanguard Group Inc., Marshall Wace LLP, Citadel Advisors LLC, AWM Investment Company Inc. and United Services Automobile Association. Company insiders that have bought Sientra stock in the last two years include Jeffrey M Nugent, Keith J Sullivan, Patrick F Williams, Paul Sean Little, R Scott Greer and Timothy Haines. View Insider Buying and Selling for Sientra.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $6.57.
How big of a company is Sientra?
Sientra has a market capitalization of $323.84 million and generates $68.13 million in revenue each year. The medical instruments supplier earns $-82,630,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Sientra employs 259 workers across the globe.View Additional Information About Sientra.
What is Sientra's official website?
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (NASDAQ SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
